Form 4: Orthofix Executive Sells Shares for Tax Obligations

Orthofix Medical Inc. President, Global Limb Recon, Patrick Fisher, sold shares of common stock to cover tax withholding obligations related to restricted stock unit settlements.

Summary

• Patrick Fisher, President, Global Limb Recon at Orthofix Medical Inc., sold shares of common stock.
• The sales were made to satisfy tax withholding obligations upon the settlement of restricted stock units.
• Transactions occurred on March 4, 2026, and March 5, 2026.
• A total of 778 shares were sold on March 4, 2026, at a weighted average price of $12.9163 per share, with prices ranging from $12.80 to $13.03.
• A total of 758 shares were sold on March 5, 2026, at a weighted average price of $12.5508 per share, with prices ranging from $12.48 to $12.72.
• The sales were executed pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors, and involved no discretion by the reporting person.
• Following these transactions, Patrick Fisher beneficially owns 50,633 shares of Orthofix common stock, which includes 41,134 previously reported restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax purposes, which typically has a neutral impact on sentiment as it does not reflect a change in the executive's investment thesis.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The sale was made without the exercise of any discretion by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a common and routine mechanism for executives to manage tax liabilities arising from the vesting of equity compensation. Such transactions are generally not indicative of a change in management's outlook on the company's prospects or a discretionary decision to reduce ownership.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not signaling a change in company fundamentals or executive confidence.

Key Dates

Recommendation

The reported transactions are routine 'sell-to-cover' sales by an executive to satisfy tax obligations related to restricted stock unit vesting. These non-discretionary sales do not reflect a change in the executive's or company's outlook and therefore do not warrant a change in investment recommendation based solely on this filing.

Keywords

Orthofix Medical Inc., OFIX, insider transaction, Form 4, stock sale, restricted stock units, tax withholding, executive compensation